Medical insurance negotiation price of lpilimumab in 2023

Ipilimumab (Ipilimumab) is an immunotherapy drug used to treat some malignancies, especially malignant melanoma (a type of skin cancer) and some other cancer types. It is an immune checkpoint inhibitor that enhances the activity of the immune system by inhibiting CTLA-4 (cytotoxic Tlymphocyte antigen4).

Ipilimumab is not currently available in the country, and medical insurance negotiations are even more difficult to negotiate. Therefore, patients cannot purchase it domestically and can only purchase it through overseas purchase channels. There are only original drugs of Ipilimumab abroad, mainly Turkish original drugs and Bristol-Myers Squibb original drugs. The price of Turkish original drugs is around 12,000 yuan, and the specification is 50mg/10ml; Bristol-Myers Squibb's original drug is priced around 11,700 yuan, and its specifications are also 50mg/10ml. The ingredients of the two drugs are the same.

CTLA-4is a protein found on the surface of T lymphocytes (a type of immune cell), where it plays a key role in regulating the activity of the immune system. However, in some cases, cancer cells can use CTLA-4 to evade the immune system's attack. Ipilimumab works by preventing CTLA-4 from binding to its ligand, thereby breaking the suppression of the immune system by cancer cells and enhancing the immune system's ability to attack cancer.

Ipilimumab is often used with other immunotherapy drugs, such as nivolumab, to increase the success of treatment. It represents an important advance in the field of tumor immunotherapy, providing new treatment options and hope for some cancer patients. However, the use of ipilimumab may cause some immune-related adverse reactions, so it needs to be performed under the supervision of a professional physician and individualized management based on the patient's specific situation.